NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Sees Significant Decline in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 1,400 shares, a decline of 64.1% from the June 30th total of 3,900 shares. Based on an average daily volume of 16,700 shares, the days-to-cover ratio is currently 0.1 days.

NRx Pharmaceuticals Price Performance

NASDAQ NRXPW remained flat at $0.07 during midday trading on Thursday. The stock has a fifty day simple moving average of $0.08 and a 200 day simple moving average of $0.13. NRx Pharmaceuticals has a fifty-two week low of $0.04 and a fifty-two week high of $0.39.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.